All articles by Catherine Eckford – Page 2
-
NewsOtarmeni Regeneron’s first genetic medicine to gain approval
Authorisation of the AAV gene therapy in the US marks a milestone for treating genetic hearing loss.
-
NewsNovel NMR-based method could facilitate safer API manufacturing
The innovative approach for detecting nitrosamine impurities in APIs addresses limitations of traditional mass-based techniques, research says.
-
NewsAmgen’s Chief Technology Officer Dr David Reese to retire
His two-decade tenure at the biopharmaceutical company has strengthened its aim for “convergent innovation” in medicine development.
-
NewsAbbVie expands US footprint with new $1.4 billion manufacturing campus
Small volume parenteral (SVP) manufacturing investment represents company’s largest capital investment to date.
-
NewsManufacturing data innovation set to accelerate medicine development
CMAC’s milestone aids the pharmaceutical industry’s transition from manual and siloed data operations to connected, intelligent manufacturing systems.
-
NewsDigital framework could optimise pharmaceutical wastewater treatment design
Combining machine learning and modelling has shown promise for supporting efficient tetracycline degradation and minimising electrical energy consumption in wastewater treatment.
-
NewsUCB expands into regenerative cell therapy through $1.15bn Neurona acquisition
Epilepsy-focused acquisition accelerates UCB’s entry into developing next generation disease-modifying therapies.
-
NewsFUJIFILM Biotechnologies opens new QC lab in Denmark
New facility expands CDMO’s quality control footprint and biomanufacturing operations.
-
NewsFood-grade materials potential alternative for one-dose pharmaceutical packaging
Food packaging films could enhance stability of hygroscopic medications, supporting improved therapeutic outcomes, study finds.
-
NewsNew FDA draft guidance to enhance safety of genome editing therapies
Recommendations support next-generation sequencing-based safety evaluation of off-target editing for personalised gene therapies.
-
NewsRegeneron and Telix collaborate to advance biologics-based radiopharmaceuticals
Potential $4.3 billion partnership deal to develop next-generation radiopharmaceutical therapies for hard-to-treat cancers.
-
NewsEuropean Commission expands Dupixent approval in chronic spontaneous urticaria
New EU authorisation gives monoclonal antibody potential as new standard of care for the chronic skin condition.
-
NewsAnalytical framework demonstrates potential in single-use chromatographic purification
Digitally-driven technique supports development of autonomous, continuous biomanufacturing technologies.
-
NewsCAR-T therapy could treat severe autoimmune diseases, shows study
Earlier intervention in severe autoimmune diseases may help prevent complications following previous ineffective treatments.
-
NewsGilead strengthens ADC capabilities with $5bn Tubulis acquisition
Deal expands the companies’ existing two-year partnership and builds Gilead’s oncology pipeline.
-
NewsSurface bioburden study offers insight on non-sterile manufacturing
Microbial load fell within the predefined limit, suggesting contamination was controlled during a single time point.
-
NewsTrump imposes 100 percent tariff on imported pharmaceuticals
US administration proffers leeway on tariffs for some drugs, with UK exports benefitting from exemption under the recent UK-US partnership.
-
NewsFDA approves Lilly’s small molecule obesity pill Foundayo
New GLP-1 therapy Foundayo is Eli Lilly’s second obesity medicine to be authorised for use in the US.
-
NewsEditas Medicine’s gene-edited therapy reni-cel sees early clinical success
The CRISPR–Cas12a autologous stem cell therapy improved total haemoglobin levels in participants with sickle cell disease.
-
NewsLilly advances neuroscience portfolio with $7.8bn acquisition of Centessa
Acquisition includes a potential best-in-class asset for excessive daytime sleepiness, broadening Lilly’s capabilities into sleep medicine.